{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:06Z","timestamp":1777859586787,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Levetiracetam (LEV) is a guideline-recommended antiepileptic that has been shown to be effective in the termination of status epilepticus. Traditionally, LEV is diluted in 100\u00a0mL of compatible fluid and administered as an intravenous (IV) piggyback over 15-60 minutes. Recent data supports the administration of LEV as an undiluted IV push. However, there is limited literature supporting the safety and tolerability of undiluted IV push administration of high dose LEV (2500\u00a0mg to 4500\u00a0mg). The purpose of this study was to further investigate safety and tolerability of IV push levetiracetam at doses 2500\u00a0mg and greater.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A retrospective chart review was conducted to evaluate adverse drug reactions following IV push administration of levetiracetam at a dose of 2500\u00a0mg or greater between the dates 8\/5\/2021 to 6\/30\/2022. During chart review, each patient was evaluated for any adverse events that occurred utilizing provider documentation, significant event forms, and\/or allergy list documentation following administration of IV push LEV.\n                    <jats:bold>Results:<\/jats:bold>\n                    Throughout the study period, 340 doses of LEV 2500\u00a0mg and greater were evaluated. Most common total dose was 3000\u00a0mg and weight-based dose was 50-59.99\u00a0mg\/kg. 119 doses of 4000\u00a0mg or greater were evaluated. 338\/340 (99.4%) doses were considered to be well-tolerated. One patient experienced erythema at the injection site and another patient was noted to have nystagmus.\n                    <jats:bold>Significance:<\/jats:bold>\n                    This study adds to the body of literature that rapid administration of undiluted LEV, including doses of 2500\u00a0mg to 4500\u00a0mg is safe and tolerable.\n                  <\/jats:p>","DOI":"10.1177\/08971900251320159","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T01:38:51Z","timestamp":1739583531000},"page":"507-510","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Safety and Tolerability of High Dose Intravenous Push Levetiracetam"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4526-1174","authenticated-orcid":false,"given":"Melissa","family":"Brandes","sequence":"first","affiliation":[{"name":"Carle Foundation Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Flack","sequence":"additional","affiliation":[{"name":"Indiana University Health Methodist Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Hays","sequence":"additional","affiliation":[{"name":"Indiana University Health West Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1905795"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03237.x"},{"key":"e_1_3_3_5_2","volume-title":"Levetiracetam Injection [package Insert]","year":"1999","unstructured":"Levetiracetam Injection [package Insert] Salisbury, MD: Jubilant Cadista Pharmaceuticals Inc; 1999."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16961"},{"issue":"6","key":"e_1_3_3_7_2","first-page":"S1","article-title":"Infusion nursing standards of practice","volume":"23","author":"Infusion Nurses Society","year":"2006","unstructured":"Infusion Nurses Society. Infusion nursing standards of practice. J Infus Nurs. 2006;23(6S):S1-S92.","journal-title":"J Infus Nurs"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01122-7"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/19418744211067908"},{"key":"e_1_3_3_10_2","first-page":"361","volume-title":"The United States Pharmacopeia, 36th rev., and the National Formulary","year":"2013","unstructured":"Pharmaceutical compounding\u2014sterile preparations (general information chapter 797). In: The United States Pharmacopeia, 36th rev., and the National Formulary, 31st ed. Rockville, MD: The United States Pharmacopeial Convention; 2013: 361\u2013398.","edition":"31"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-019-00708-5"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808331351"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.08.046"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251320159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251320159","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251320159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:47Z","timestamp":1777509227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251320159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/08971900251320159"],"URL":"https:\/\/doi.org\/10.1177\/08971900251320159","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}